Ascorbic Acid Levels in MDS, AML, and CMML Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/18/2018 |
| Start Date: | November 1, 2017 |
| End Date: | October 31, 2018 |
| Contact: | Dan Rogers, CCRC, CIP |
| Email: | dan.rogers@vai.org |
| Phone: | 616-234-5457 |
Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research
This study is a non-interventional, specimen collection translational study to evaluate
vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic
Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.
vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic
Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.
Our collaborators published that hematological cancer patients with myelodysplastic syndrome
(MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency. Their study
analyzed specimens from a cohort of patients in Copenhagen. We aim to determine if those
results are conserved in another population/geographical location.
(MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency. Their study
analyzed specimens from a cohort of patients in Copenhagen. We aim to determine if those
results are conserved in another population/geographical location.
Inclusion Criteria:
- Patients actively receiving treatment for acute myeloid leukemia (AML),
myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
- Patients diagnosed with AML, MDS, or CMML and are treatment naïve.
- Patients who are 18 years old or older.
Exclusion Criteria:
- Patients deemed as too ill to participate as determined by the clinical investigator.
- Non-English speaking patients
- Patients unable to provide informed consent.
We found this trial at
2
sites
5950 Metro Way
Wyoming, Michigan 49519
Wyoming, Michigan 49519
Principal Investigator: Michael Zakem, DO
Phone: 616-252-5127
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Brett Brinker, MD
Phone: 616-954-5550
Click here to add this to my saved trials